BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 12917349)

  • 1. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity.
    Stebbins CC; Watzl C; Billadeau DD; Leibson PJ; Burshtyn DN; Long EO
    Mol Cell Biol; 2003 Sep; 23(17):6291-9. PubMed ID: 12917349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.
    Yusa S; Catina TL; Campbell KS
    J Immunol; 2002 May; 168(10):5047-57. PubMed ID: 11994457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells.
    Yusa S; Campbell KS
    J Immunol; 2003 May; 170(9):4539-47. PubMed ID: 12707331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of killer cell inhibitory receptor-mediated signal transduction machinery in a cell-free model system.
    Cho HI; Park CG; Kim J
    Arch Biochem Biophys; 1999 Aug; 368(2):221-31. PubMed ID: 10441372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals.
    Vyas YM; Maniar H; Lyddane CE; Sadelain M; Dupont B
    J Immunol; 2004 Aug; 173(3):1571-8. PubMed ID: 15265884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors.
    Bruhns P; Marchetti P; Fridman WH; Vivier E; Daëron M
    J Immunol; 1999 Mar; 162(6):3168-75. PubMed ID: 10092767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158).
    Long EO; Barber DF; Burshtyn DN; Faure M; Peterson M; Rajagopalan S; Renard V; Sandusky M; Stebbins CC; Wagtmann N; Watzl C
    Immunol Rev; 2001 Jun; 181():223-33. PubMed ID: 11513144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization.
    Riteau B; Barber DF; Long EO
    J Exp Med; 2003 Aug; 198(3):469-74. PubMed ID: 12885870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2).
    Yusa S; Catina TL; Campbell KS
    J Immunol; 2004 Jun; 172(12):7385-92. PubMed ID: 15187115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase.
    Marti F; Xu CW; Selvakumar A; Brent R; Dupont B; King PD
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11810-5. PubMed ID: 9751747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation.
    Binstadt BA; Brumbaugh KM; Dick CJ; Scharenberg AM; Williams BL; Colonna M; Lanier LL; Kinet JP; Abraham RT; Leibson PJ
    Immunity; 1996 Dec; 5(6):629-38. PubMed ID: 8986721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous clustering and tyrosine phosphorylation of NK cell inhibitory receptor induced by ligand binding.
    Faure M; Barber DF; Takahashi SM; Jin T; Long EO
    J Immunol; 2003 Jun; 170(12):6107-14. PubMed ID: 12794140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors.
    Binstadt BA; Billadeau DD; Jevremović D; Williams BL; Fang N; Yi T; Koretzky GA; Abraham RT; Leibson PJ
    J Biol Chem; 1998 Oct; 273(42):27518-23. PubMed ID: 9765283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1.
    Lowin-Kropf B; Kunz B; Beermann F; Held W
    J Immunol; 2000 Aug; 165(3):1314-21. PubMed ID: 10903732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment of SHP-1 protein tyrosine phosphatase and signalling by a chimeric T-cell receptor-killer inhibitory receptor.
    Christensen MD; Geisler C
    Scand J Immunol; 2000 Jun; 51(6):557-64. PubMed ID: 10849365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244).
    Eissmann P; Beauchamp L; Wooters J; Tilton JC; Long EO; Watzl C
    Blood; 2005 Jun; 105(12):4722-9. PubMed ID: 15713798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actin cytoskeleton controls the efficiency of killer Ig-like receptor accumulation at inhibitory NK cell immune synapses.
    Standeven LJ; Carlin LM; Borszcz P; Davis DM; Burshtyn DN
    J Immunol; 2004 Nov; 173(9):5617-25. PubMed ID: 15494512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases.
    Gupta N; Scharenberg AM; Burshtyn DN; Wagtmann N; Lioubin MN; Rohrschneider LR; Kinet JP; Long EO
    J Exp Med; 1997 Aug; 186(3):473-8. PubMed ID: 9236201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
    Lin Chua H; Brahmi Z
    Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
    Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM
    J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.